• Sunday, February 6, 2022 @ 12:00 am

First partner validation of vamorolone in DMD through a lucrative licensing agreement with Sperogenix for the Greater China Region in a deal valued at USD 124 mn plus double-digit sales royalties. Vamorolone US and EU DMD filings are on track for H1 2022. Santhera provides substantial equity upside while vamorolone in DMD has been largely de-risked.

Key catalysts include

  1. Vamorolone US DMD filing (Q1 2022)
  2. Vamorolone EU DMD filing (end Q2 2022)
  3. Vamorolone US DMD approval (Q4 2022)

Read full Santhera Valuation Report "On a mission with a VISION" update

You may also be interested in